The impact of intensive management on pain intensity in patients with rheumatoid arthritis and psoriatic arthritis: secondary analysis of three clinical trials.
{"title":"The impact of intensive management on pain intensity in patients with rheumatoid arthritis and psoriatic arthritis: secondary analysis of three clinical trials.","authors":"Fowzia Ibrahim, David L Scott, Ian C Scott","doi":"10.1186/s41927-025-00493-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Understanding the impact of intensive treatment on pain in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is crucial to informing the application of evidence-based arthritis pain care. The impact of intensive treatment on inflammatory arthritis pain has received relatively limited attention. We addressed this through a detailed secondary analysis of three trials evaluating varying intensities of disease-modifying anti-rheumatic drug treatment. We considered a range of pain outcomes of clinical relevance to patients, including the achievement of mild endpoint pain scores and clinically-meaningful pain reductions.</p><p><strong>Methods: </strong>The trials comprised MIPA in PsA, CARDERA in early RA, and TITRATE in established RA. Pain was measured using a 100-mm pain intensity visual analogue scale (VAS). The impact of intensive treatment on (a) patients achieving \"mild\" endpoint pain intensity scores (of ≤ 34), b) mean changes in pain intensity scores, and (c) patients achieving ≥ 30% reductions in pain intensity scores was evaluated using t-tests, chi-squared tests, and regression models (with the latter adjusting for relevant potential confounding variables).</p><p><strong>Results: </strong>From MIPA, CARDERA, and TITRATE 128, 379, and 258 patients had endpoint outcome data available and were included in this secondary analysis. In all trials, significantly more patients achieved mild endpoint pain intensity scores with intensive vs. control treatment (MIPA 70% vs. 42%, P = 0.003; CARDERA 71% vs. 56%, P = 0.011; TITRATE 67% vs. 50%, P = 0.008). In the two trials employing the most intensive management strategies (CARDERA; TITRATE) overall reductions in pain scores were significantly greater (6.6 to 6.8 units in adjusted linear regression models), and significantly more achieved ≥ 30% reductions in pain with intensive vs. control treatment (adjusted logistic regression models: CARDERA odds ratio [OR] 1.9, P = 0.009; TITRATE OR 2.2, P = 0.002).</p><p><strong>Conclusions: </strong>Intensive treatment is an important component of improving pain in patients with active RA and PsA. Our findings support EULAR guidance that optimising disease activity is crucial for pain control. As approximately one third of patients receiving active treatment had moderate/high endpoint pain intensity levels across trials, additional pain management strategies that complement intensive treatment are needed.</p><p><strong>Trial registration: </strong>Current Controlled Trials CARDERA ISRCTN32484878 (25/10/2000), MIPA ISRCTN54376151 (04/02/2002), and TITRATE ISRCTN70160382 (16/1/2014).</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"55"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093695/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41927-025-00493-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Understanding the impact of intensive treatment on pain in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is crucial to informing the application of evidence-based arthritis pain care. The impact of intensive treatment on inflammatory arthritis pain has received relatively limited attention. We addressed this through a detailed secondary analysis of three trials evaluating varying intensities of disease-modifying anti-rheumatic drug treatment. We considered a range of pain outcomes of clinical relevance to patients, including the achievement of mild endpoint pain scores and clinically-meaningful pain reductions.
Methods: The trials comprised MIPA in PsA, CARDERA in early RA, and TITRATE in established RA. Pain was measured using a 100-mm pain intensity visual analogue scale (VAS). The impact of intensive treatment on (a) patients achieving "mild" endpoint pain intensity scores (of ≤ 34), b) mean changes in pain intensity scores, and (c) patients achieving ≥ 30% reductions in pain intensity scores was evaluated using t-tests, chi-squared tests, and regression models (with the latter adjusting for relevant potential confounding variables).
Results: From MIPA, CARDERA, and TITRATE 128, 379, and 258 patients had endpoint outcome data available and were included in this secondary analysis. In all trials, significantly more patients achieved mild endpoint pain intensity scores with intensive vs. control treatment (MIPA 70% vs. 42%, P = 0.003; CARDERA 71% vs. 56%, P = 0.011; TITRATE 67% vs. 50%, P = 0.008). In the two trials employing the most intensive management strategies (CARDERA; TITRATE) overall reductions in pain scores were significantly greater (6.6 to 6.8 units in adjusted linear regression models), and significantly more achieved ≥ 30% reductions in pain with intensive vs. control treatment (adjusted logistic regression models: CARDERA odds ratio [OR] 1.9, P = 0.009; TITRATE OR 2.2, P = 0.002).
Conclusions: Intensive treatment is an important component of improving pain in patients with active RA and PsA. Our findings support EULAR guidance that optimising disease activity is crucial for pain control. As approximately one third of patients receiving active treatment had moderate/high endpoint pain intensity levels across trials, additional pain management strategies that complement intensive treatment are needed.
Trial registration: Current Controlled Trials CARDERA ISRCTN32484878 (25/10/2000), MIPA ISRCTN54376151 (04/02/2002), and TITRATE ISRCTN70160382 (16/1/2014).
背景:了解强化治疗对类风湿关节炎(RA)和银屑病关节炎(PsA)患者疼痛的影响对循证关节炎疼痛护理的应用至关重要。强化治疗对炎症性关节炎疼痛的影响受到相对有限的关注。我们通过对三个试验的详细二次分析来解决这个问题,这些试验评估了不同强度的改善疾病的抗风湿药治疗。我们考虑了一系列与患者临床相关的疼痛结局,包括达到轻度终点疼痛评分和临床有意义的疼痛减轻。方法:试验包括MIPA治疗PsA, CARDERA治疗早期RA, TITRATE治疗晚期RA。采用100 mm疼痛强度视觉模拟量表(VAS)测量疼痛。强化治疗对(a)达到“轻度”终点疼痛强度评分(≤34)的患者的影响,b)疼痛强度评分的平均变化,以及(c)疼痛强度评分降低≥30%的患者的影响采用t检验、卡方检验和回归模型(后者调整了相关的潜在混杂变量)进行评估。结果:来自MIPA、CARDERA和TITRATE的128例、379例和258例患者获得了终点结局数据,并纳入了该次要分析。在所有试验中,强化治疗与对照组相比,获得轻度终点疼痛强度评分的患者明显更多(MIPA 70% vs 42%, P = 0.003;CARDERA 71% vs. 56%, P = 0.011;滴定率67% vs. 50%, P = 0.008)。在采用最集约化管理策略的两个试验中(CARDERA;TITRATE)疼痛评分的总体降低明显更大(调整线性回归模型为6.6至6.8个单位),强化治疗与对照治疗相比,疼痛降低≥30%的效果更显著(调整逻辑回归模型:CARDERA优势比[OR] 1.9, P = 0.009;滴定或2.2,p = 0.002)。结论:强化治疗是改善活动期RA和PsA患者疼痛的重要组成部分。我们的研究结果支持EULAR的指导,即优化疾病活动对疼痛控制至关重要。由于大约三分之一接受积极治疗的患者在试验中有中等/高终点疼痛强度水平,因此需要额外的疼痛管理策略来补充强化治疗。试验注册:当前对照试验CARDERA ISRCTN32484878(2000年10月25日),MIPA ISRCTN54376151(2002年2月4日)和TITRATE ISRCTN70160382(2014年1月16日)。